Clinical and laboratory study of an episode of cefotetan-induced severe hemolytic anemia
| Autor: | Pier Luigi Piccoli, Giuseppe Aprili, Marzia De Gironcoli, Massimo Franchini, Giorgio Gandini, Fausto Bressan, Annachiara Giuffrida |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Hemolytic anemia
medicine.medical_specialty Anemia Hemolytic Erythrocytes Cefotetan medicine.drug_class Cephalosporin Antibiotics Gastroenterology Antibodies Perioperative Care Immune Hemolytic Anemia Internal medicine medicine Humans biology business.industry Hematology Antibiotic Prophylaxis Middle Aged medicine.disease Immune complex Discontinuation Anti-Bacterial Agents Cephalosporins biology.protein Female Antibody business medicine.drug |
| Zdroj: | Hematology (Amsterdam, Netherlands). 9(1) |
| ISSN: | 1024-5332 |
| Popis: | BACKGROUND Cephalosporins are frequently associated with positive direct antiglobulin tests (DAT) and may rarely cause immune hemolytic anemia (IHA). We describe a patient who developed hemolytic anemia while she was receiving intravenous cefotetan. STUDY DESIGN AND METHODS Immunohematologic studies of drug-dependent antibodies were performed by using cefotetan-treated red blood cells (RBCs) and untreated RBCs in the presence of cefotetan. RESULTS The patient's serum contained antibodies that reacted with both drug-coated RBCs (adsorption mechanism) and with uncoated RBCs when cefotetan was added to the serum (immune complex mechanism). The prompt recognition of the problem and discontinuation of the drug prevented the onset of renal failure and rapidly resolved the hemolytic reaction. CONCLUSION Our report underlines the importance of close laboratory and immunohematologic monitoring of patients treated with cephalosporins in order to recognize swiftly any hemolytic reaction due to these antibiotics thus reducing the chance of serious sequelae. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|